Velocity appoints ex-IQVIA and Science 37 Executive Mike Zaranek as CFO
July 16 2024 - 7:04AM
Velocity Clinical Research (“Velocity”), the leading
multi-specialty clinical sites business, today announces it has
appointed Mike Zaranek as Chief Financial Officer (CFO). Reporting
to Velocity President and CEO Paul Evans with immediate effect,
Zaranek will direct the company’s financial goals and accounting,
and advise on the Company’s strategic direction.
Mike brings nearly three decades of experience in the
life-sciences industry in senior financial and corporate
development leadership roles, having previously held roles at IQVIA
and Science 37.
Paul Evans, President and Chief Executive of
Velocity, said: “Velocity has grown exponentially in the
past three years since the GHO acquisition. That brings with it a
different set of challenges to manage whilst ensuring we deliver on
strategic goals. Attracting top talent from major organizations,
like Mike, demonstrates the ambitious goals we have as an
organization to scale, and scale for a purpose. Mike and his team
are a strategic part of that and I look forward to working with him
to deliver Velocity’s next stage of growth.”
Mike served as CFO at Science 37, where he was instrumental in
shaping the financial strategies that supported the company's
leadership in decentralized clinical trials and Nasdaq Global
Market debut as a publicly traded company in 2021.
Mike Zaranek, Velocity CFO, said: “The Velocity
team’s commitment to patient care and customer partnership has
delivered considerable success to date. I’m looking forward to
supporting the next phase of profitable growth by ensuring we scale
our processes, systems and teams in a manner that delivers value
for our customers and investigators.”
Prior to Science 37, Mike was Vice President of Finance for
IQVIA's Contract Sales & Medical Solutions, a nearly $1 billion
in annual global revenue business segment, and has held corporate
development roles, with significant experience in global
acquisitions as well as capital markets transactions. He holds a
Bachelor of Science degree in Accounting from The Pennsylvania
State University and a Master of Business Administration degree
from Duke University.
Velocity operates an integrated site network of 90 locations
across the U.S., U.K., Germany, and Poland. It has access to more
than 220 principal investigators across a range of therapeutic
areas and a database of more than one million patients.
Furthermore, with its tech hub in Hyderabad, India, Velocity is the
first clinical trials site business to develop proprietary and
dedicated patient recruitment and engagement technology.
Notes to Editors
About Velocity Clinical Research
Velocity is the leading integrated site organization for
clinical trials. With 90 sites and more than 220 investigators,
Velocity partners with pharmaceutical and biotechnology companies
to research new drugs, medical devices, diagnostics, and
combination products that could improve human health and wellbeing.
Velocity offers unified research site solutions to efficiently
provide the right patients, investigators, and research staff for
clinical trials across the U.S. and Europe.
The company also operates a technology hub in India, where it is
unlocking a new era in clinical research by developing innovative
systems to leverage expansive site, patient, and historical
performance data. To learn more about how Velocity delivers
high-quality data, exemplary patient care, and unprecedented
efficiency for clinical trials at any scale, visit
VelocityClinical.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/7cbe602e-c79c-459f-b98a-cbe78fc8df44
Media contact
Katie Evans
Corporate communications
kevans@velocityclinical.com